Therapeutic Asset Ratings

472 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Irinotecan Gastrointestinal Diseases	Pfizer	P3	B (60)
Irinotecan Intestinal Diseases	Pfizer	P3	B (60)
Irinotecan Rectal Diseases	Pfizer	P3	B (60)
Lorlatanib Advanced Malignancies	Pfizer	P3	B (60)
Mevrometostat Cancer of the Prostate	Pfizer	P3	B (60)
Mevrometostat Hormone Sensitive Prostate Cancer	Pfizer	P3	B (60)
Mevrometostat Metastatic Castration Sensitive Prostate Cancer (mCSPC)	Pfizer	P3	B (60)
pf-08634404 Colonic Diseases	Pfizer	P3	B (60)
pf-08634404 Digestive System Diseases	Pfizer	P3	B (60)
pf-08634404 Intestinal Diseases	Pfizer	P3	B (60)
pf-08634404 Intestinal Neoplasms	Pfizer	P3	B (60)
pf-08634404 Neoplasms by Site	Pfizer	P3	B (60)
pf-08634404 Rectal Diseases	Pfizer	P3	B (60)
pf-08653944 Overweight	Pfizer	P3	B (60)
Rimegepant Menstrual Migraine	Pfizer	P3	B (60)
(+)-VINCRISTINE Colonic Diseases	Pfizer	P3	B (60)
(+)-VINCRISTINE Digestive System Diseases	Pfizer	P3	B (60)
(+)-VINCRISTINE Gastrointestinal Diseases	Pfizer	P3	B (60)
(+)-VINCRISTINE Intestinal Diseases	Pfizer	P3	B (60)
(+)-VINCRISTINE Rectal Diseases	Pfizer	P3	B (60)
CIS-DIAMMINEDICHLOROPLATINUM II Colorectal Neoplasms	Pfizer	P2	B (60)
FULVESTRANT Liposarcoma	Pfizer	P2	B (60)
Hycamtin Rhabdoid Tumor	Pfizer	P2	B (60)
Omeprazole T2DM (Type 2 Diabetes Mellitus)	Pfizer	P2	B (60)
Palbociclib Non-Small Cell Lung Cancer	Pfizer	P2	B (60)

Showing 76 to 100 of 472 assets